Anne Floquet
Overview
Explore the profile of Anne Floquet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
4384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, et al.
Nat Commun
. 2024 Jun;
15(1):4753.
PMID: 38834579
No abstract available.
2.
Fontanges Q, Dubos P, Lesluyes T, Laizet Y, Velasco V, Melendez B, et al.
Genes Chromosomes Cancer
. 2024 Mar;
63(3):e23229.
PMID: 38481055
A close relationship has been demonstrated between genomic complexity and clinical outcome in uterine smooth muscle tumors. We studied the genomic profiles by array-CGH of 28 fumarate hydratase deficient leiomyomas...
3.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, et al.
Nat Commun
. 2024 Mar;
15(1):1985.
PMID: 38443333
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess...
4.
Fabbro M, Lamy P, Touraine C, Floquet A, Ray-Coquard I, Mollevi C
Front Oncol
. 2024 Jan;
13:1308630.
PMID: 38273857
HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum...
5.
Houessou A, Aoudji A, Biaou G, Floquet A
Heliyon
. 2023 Aug;
9(8):e19019.
PMID: 37636437
The role that owner-managers' managerial capabilities play in agricultural firms' strategic change and performance is still unclear. A firm's market opportunities seizing capability (OSC) is a source of competitiveness and...
6.
Sertier A, Ferrari A, Pommier R, Treilleux I, Boyault S, Devouassoux-Shisheboran M, et al.
Cancer Res Commun
. 2023 Jun;
3(5):830-841.
PMID: 37377900
Significance: We have provided a detailed characterization of the genomic landscape of CS and identified EMT as a common mechanism associated with phenotypic divergence, linking CS heterogeneity to genetic, transcriptomic,...
7.
Richez B, Cantarel C, Durrieu F, Soubeyran I, Blanchi J, Pernot S, et al.
Int J Environ Res Public Health
. 2023 Jun;
20(11).
PMID: 37297553
Infection of SARS-CoV-2 among health workers (HWs) in contact with cancer patients has been a major issue since the beginning of the pandemic. We aimed to assess the serological immune...
8.
Hanvic B, Lecuru F, Vanacker H, Pautier P, Narducci F, Cherifi F, et al.
Gynecol Oncol
. 2023 May;
174:190-199.
PMID: 37210929
Objective: Identifying prognostic factors and evaluating the impact of adjuvant chemotherapy in patients with sex cord stromal tumors (SCST) is crucial. In this study, we aimed to address these challenges....
9.
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, et al.
Gynecol Oncol
. 2023 Apr;
173:98-105.
PMID: 37105063
Background: PARP inhibitors (PARPi) have revolutionized the management of high-grade epithelial ovarian cancer (HGOC) treatment. However, a significant number of patients relapse or progress under PARPi, leading to the introduction...
10.
Collineau B, Genestie C, Croce S, Meeus P, Floquet A, Guyon F, et al.
Bull Cancer
. 2023 Mar;
110(4):440-449.
PMID: 36863922
Uterine leiomyosarcomas represent the most common uterine sarcomas. The prognosis is poor with metastatic recurrence in more than half of the cases. The purpose of this review is to make...